

ASX ANNOUNCEMENT
Monday, 05 October 2026

Section 708A Cleansing Notice

This Notice is given by IDT Australia Limited (ASX: IDT) (IDT or the Company) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act):

The Company hereby confirms that:

- a) it has on 2 October 2026 issued a total of 1,388,545 fully paid ordinary shares (Shares), to its employees upon exercise of Performance Rights, in accordance with the terms of the IDT Employee Performance Rights Plan;
- b) the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- d) as at the date of this notice, the Company has complied with:
 - I. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - II. section 674 and 674A of the Act; and
- e) as at the date of this notice, there is no information that is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Act) which is required to be disclosed by the Company.

The details of this allotment can be found within the Appendix 2A, also announced on this day.

This announcement is authorised by the IDT Australia Limited Board.

Ends..../

For investor and media enquiries, please contact:

Brendon Lau

E: brendon@vantagepointpartners.com.au

M: +61 409 341 613

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia’s beliefs, assumptions, and expectations and on information currently available to IDT Australia.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT’s facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.



All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.